ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Summary

This study is a multicenter, open-label, uncontrolled, phase II trial aimed to establish the safety and tolerability of venetoclax, atezolizumab and obinutuzumab combination in Richter Transformation of CLL.

Timeline

Start

2019-10-04

Primary completion

2026-09

Completion

2026-12

Publications

• Tedeschi A, Frustaci AM, Condoluci A, Coscia M, Chiarle R, Zinzani PL, Motta M, Gaidano G, Quaresmini G, Scarfo L, Catania G, Deodato M, Jones R, Tabanelli V, Griggio V, Stussi G, Calleri A, Pini K, Cairoli R, Zenz T, Signori A, Zucca E, Rossi D, Montillo M. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024 Oct;25(10):1298-1309. doi: 10.1016/S1470-2045(24)00396-6. Epub 2024 Sep 10.

Drugs

Indications